Log on / register
Feedback | Support | My details
The protein C pathway: implications for the design of the RESPOND study.
Vangerow B, Shorr AF, Wyncoll D, Janes J, Nelson DR, Reinhart K
Crit Care 2007, 11 Suppl 5:S4
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.
37%37%


 Commentary    
Protein C as a surrogate end-point for clinical trials of sepsis
Liu KD, Matthay MA
Critical Care 2008, 12:139 (24 April 2008)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles]
2.
37%37%


 Introduction    
Introduction: severe sepsis and drotrecogin alfa (activated)
Artigas A, Martin CD
Critical Care 2007, 11(Suppl 5):S1 (19 December 2007)
 [Full text] [PDF] [PubMed] [Related articles]
3.
37%37%


 Review    
Recombinant human activated protein C: current insights into its mechanism of action
Levi M, van der Poll T
Critical Care 2007, 11(Suppl 5):S3 (19 December 2007)
 [Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]

You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.